ATTO - Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.
ATTO - Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5M in a US IPO